Ss Innovations International, Inc (SSII)
NASDAQ:SSII
Top Page
SS Innovations International
(NASDAQ:SSII)
Select Model
Select Model
Rating:49Neutral
Price Target:
$4.50
▼(-29.91% Downside)
Action:ReiteratedDate:03/18/26
The score is held back primarily by weak profitability and worsening cash burn despite rapid revenue growth and a strengthened balance sheet. Technicals are neutral-to-mixed with high volatility, while valuation is constrained by ongoing losses. Positive corporate events (approvals, adoption milestones, and fresh capital) provide meaningful upside support but are secondary to financial execution risk.
Positive Factors
Revenue growth & gross margin
Durable, double‑digit revenue expansion and a materially higher gross margin indicate the SSi Mantra is gaining commercial traction and achieving scale. Higher gross profit dollars support recurring consumables, service revenue and a pathway to operating leverage as installations and utilization grow.
Negative Factors
Worsening cash burn
Negative and deteriorating operating/free cash flow is a structural risk: sustained cash burn forces reliance on external funding or rapid margin improvement. If revenue growth doesn’t convert to positive cash generation, liquidity constraints could impair product roll‑outs and service expansion over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth & gross margin
Durable, double‑digit revenue expansion and a materially higher gross margin indicate the SSi Mantra is gaining commercial traction and achieving scale. Higher gross profit dollars support recurring consumables, service revenue and a pathway to operating leverage as installations and utilization grow.
Read all positive factors
SS Innovations International (SSII) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$938.74M
Dividend YieldN/A
Average Volume (3M)93.70K
Price to Earnings (P/E)―
Beta (1Y)9.80
Revenue Growth159.43%
EPS Growth67.42%
CountryUS
Employees378
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.01
Shares Outstanding194,356,690
10 Day Avg. Volume86,548
30 Day Avg. Volume93,699
Financial Highlights & Ratios
PEG Ratio2.12
Price to Book (P/B)28.24
Price to Sales (P/S)25.45
P/FCF Ratio-48.61
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue22.23
Enterprise Value/Gross Profit49.12
Enterprise Value/Ebitda-149.79
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SS Innovations International Business Overview & Revenue Model
Company Description
SS Innovations International, Inc. develops surgical robotic systems. It also develops SSI Mantra, a surgical robotic system; SSI Mudra, a range of surgical instruments that supports in surgical procedures, including robotic cardiac surgery; SSI M...
How the Company Makes Money
SSII makes money primarily by selling or placing its robotic surgical systems with healthcare providers and generating recurring revenue from ongoing use of those systems. Key revenue streams typically include: (1) system-related revenue from upfr...
SS Innovations International Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 42.41M | 20.65M | 5.88M | 1.46M | 0.00 |
| Gross Profit | 18.40M | 8.45M | 713.45K | 489.59K | -18.79K |
| EBITDA | -7.08M | -17.74M | -20.26M | -5.31M | -1.47M |
| Net Income | -12.13M | -19.15M | -20.94M | -5.60M | -1.48M |
Balance Sheet | |||||
| Total Assets | 74.23M | 42.39M | 25.48M | 6.98M | 428.61K |
| Cash, Cash Equivalents and Short-Term Investments | 3.21M | 466.50K | 7.03M | 217.18K | 405.77K |
| Total Debt | 2.92M | 18.20M | 8.22M | 8.27M | 145.00K |
| Total Liabilities | 36.01M | 28.93M | 11.18M | 9.66M | 287.28K |
| Stockholders Equity | 38.22M | 13.46M | 14.30M | -2.68M | 141.33K |
Cash Flow | |||||
| Free Cash Flow | -22.20M | -10.16M | -15.81M | -1.44M | -363.03K |
| Operating Cash Flow | -18.54M | -9.50M | -15.36M | -5.99M | -363.03K |
| Investing Cash Flow | -3.66M | -661.48K | -453.33K | 240.82K | 38.15K |
| Financing Cash Flow | 26.17M | 9.43M | 22.80M | 5.90M | 569.95K |
SS Innovations International Technical Analysis
Negative
6.42
Price Trends
4.68
Positive
5.46
Negative
6.00
Negative
Market Momentum
0.07
Negative
51.34
Neutral
57.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SSII, the sentiment is Negative. The current price of 6.42 is above the 20-day moving average (MA) of 4.77, above the 50-day MA of 4.68, and above the 200-day MA of 6.00, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 51.34 is Neutral, neither overbought nor oversold. The STOCH value of 57.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SSII.
SS Innovations International Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $1.75B | -42.28 | -201.79% | ― | 24.76% | -10.41% | |
59 Neutral | $1.73B | 211.68 | 2.44% | ― | 9.81% | -1067.00% | |
56 Neutral | $1.14B | 26.78 | 4.68% | 2.02% | 4.69% | -51.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $938.74M | ― | -30.23% | ― | 159.43% | 67.42% | |
47 Neutral | $744.30M | -1.85 | -39.90% | ― | 4.99% | -7151.40% | |
45 Neutral | $1.66B | -7.22 | -141.98% | ― | 17.87% | -57.03% |
* Healthcare Sector Average
SSII
SS Innovations International
4.86
-4.69
-49.11%
CNMD
Conmed
37.08
-22.82
-38.10%
AORT
Artivion
36.12
11.41
46.18%
IART
Integra Lifesciences
9.55
-12.27
-56.23%
TNDM
Tandem Diabetes Care
24.26
4.60
23.40%
ESTA
Establishment Labs Holdings
59.57
19.65
49.22%
SS Innovations International Corporate Events
Business Operations and StrategyProduct-Related Announcements
SS Innovations Gains Telesurgery Approvals in Indonesia, Philippines
Positive
Mar 18, 2026
On March 18, 2026, SS Innovations International announced that its SSi Mantra surgical robotic system has been approved for telesurgeries in Indonesia and the Philippines, marking an expansion beyond its primary base in India. The company also dis...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
SS Innovations Reports Strong 2025 Growth, Raises New Capital
Positive
Mar 10, 2026
On March 10, 2026, SS Innovations reported unaudited results for the fourth quarter and full year 2025, highlighting a 79.1% year-over-year revenue increase in the quarter to $14.5 million and a 105.7% rise in full-year revenue to $42.5 million, d...
Business Operations and StrategyPrivate Placements and Financing
SS Innovations Raises Capital to Fund Global Expansion
Positive
Mar 9, 2026
On March 6, 2026, SS Innovations International completed a privately negotiated sale of 5,774,839 shares of common stock, raising approximately $18.6 million in gross proceeds, led by significant insider participation from its chairman, vice chair...
Business Operations and StrategyFinancial Disclosures
SS Innovations Reports Surging Preliminary 2025 Robotics Revenue
Positive
Jan 13, 2026
On January 13, 2026, SS Innovations International announced preliminary unaudited results indicating a sharp acceleration in sales of its SSi Mantra surgical robotic system for the fourth quarter and full year ended December 31, 2025. The company ...
Business Operations and StrategyProduct-Related Announcements
SS Innovations Unveils New 5mm Instruments for Robotic Surgery
Positive
Jan 6, 2026
On January 6, 2026, SS Innovations announced it had completed development of five new 5-millimeter surgical instruments—spatula cautery, hook cautery, needle driver, bipolar forceps, and grasping forceps—for use with its SSi Mantra rob...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.